Key facts
- This page summarizes GSK plc's Form 4 filing for Wave Life Sciences Ltd. (WVE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 Dec 2025, 16:32.
GSK plc - 11 Dec 2025 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- WVE
- Reported as of
- 11 Dec 2025
- Net transaction value
- +$27,930,000
- SEC form
- 4
- Accepted by SEC
- 15 Dec 2025, 16:32:10 UTC
- Prior SEC filing
- 01 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Victoria Whyte, Authorized Signatory, GSK plc
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
GSK plc filed Form 4 for Wave Life Sciences Ltd. (WVE) on 15 Dec 2025.
Change
- Previous filing in this sequence was filed on 01 Oct 2024.
- Current net transaction value: +$27,930,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001131399
Primary reporting owner
GSK plc
- Relationship
- 10%+ Owner
- Address
- 79 NEW OXFORD STREET, LONDON, UNITED KINGDOM
- Signature
- /s/ Victoria Whyte, Authorized Signatory, GSK plc
- Signature date
- 15 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WVE
transaction
Ordinary Shares
Purchase
- Transaction value
- $27,930,000
- Shares
- +1,470,000
- Change %
- +8.8%
- Price
- $19.00
- Shares after
- 18,245,691
- Date
- 11 Dec 2025
- Ownership
- By Corporation
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
GSK plc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the "Reporting Person").